Expand BTAI Menu
BTAI MENU

BTAI Latest Press Releases

-- April 24, 2024 --

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting Globe Newswire 10:30 AM

-- April 22, 2024 --

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential Globe Newswire 7:00 AM

-- April 10, 2024 --

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia Globe Newswire 7:00 AM

-- March 25, 2024 --

BioXcel Therapeutics Announces $25 Million Registered Direct Offering Globe Newswire 7:00 AM

-- March 15, 2024 --

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine Globe Newswire 7:00 AM

-- March 12, 2024 --

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 Globe Newswire 7:00 AM

-- March 1, 2024 --

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 Globe Newswire 7:00 AM

-- February 14, 2024 --

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies Globe Newswire 8:30 AM

-- February 13, 2024 --

BioXcel Therapeutics Announces Termination of Proposed Public Offering Globe Newswire 9:00 AM

-- February 12, 2024 --

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) Globe Newswire 7:14 AM

-- February 9, 2024 --

BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 9:00 PM

-- February 8, 2024 --

BioXcel Therapeutics Announces Proposed Public Offering Globe Newswire 4:01 PM

-- February 6, 2024 --

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA Globe Newswire 7:00 AM

-- February 5, 2024 --

BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine Globe Newswire 7:00 AM

-- December 12, 2023 --

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today Globe Newswire 7:00 AM

-- December 11, 2023 --

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs Globe Newswire 7:00 AM

-- December 1, 2023 --

Moore Kuehn, PLLC Encourages BioXcel Therapeutics, Inc. Investors to Contact Law Firm PRNewswire 7:29 PM

-- November 30, 2023 --

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023 Globe Newswire 7:00 AM